Core Insights - ABVC BioPharma, Inc. announced the acquisition of TT Life Company by its subsidiary AiBtl BioPharma Inc. for approximately 5 per share [1][2] - The acquisition aims to enhance AiBtl's capabilities in precision medicine, combining its global development expertise with TT Life's design and manufacturing strengths [2][3] - TT Life Company is projected to achieve targeted sales of $10 million in 2024, with a net profit margin of 11% [5] Company Overview - ABVC BioPharma is a clinical-stage biopharmaceutical company with a pipeline of six drugs and one medical device under development, utilizing in-licensed medicine from renowned research institutions [6] - AiBtl BioPharma focuses on integrating health and resort industries, aiming to deliver AI-powered products and services [4] - TT Life Company specializes in precision medicine, known for its innovative cell-related products and strong marketing presence in Asia, particularly Malaysia [5]
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share